Cargando…
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
BACKGROUND: CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of patients treated with checkpoint inhibitors. METHOD...
Autores principales: | DeLeon, Thomas T., Almquist, Daniel R., Kipp, Benjamin R., Langlais, Blake T., Mangold, Aaron, Winters, Jennifer L., Kosiorek, Heidi E., Joseph, Richard W., Dronca, Roxana S., Block, Matthew S., McWilliams, Robert R., Kottschade, Lisa A., Rumilla, Kandelaria M., Voss, Jesse S., Seetharam, Mahesh, Sekulic, Aleksandar, Markovic, Svetomir N., Bryce, Alan H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083309/ https://www.ncbi.nlm.nih.gov/pubmed/32196516 http://dx.doi.org/10.1371/journal.pone.0230306 |
Ejemplares similares
-
Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients
por: Dronca, Roxana, et al.
Publicado: (2015) -
BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance)
por: Slostad, Jessica A., et al.
Publicado: (2021) -
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
por: Vera Aguilera, Jesus, et al.
Publicado: (2020) -
Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era
por: Youland, Ryan S., et al.
Publicado: (2017) -
18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma
por: Youland, Ryan S., et al.
Publicado: (2017)